SCHEMBL2296845

SCHEMBL2296845

CNC(=O)c1ccc(F)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.51
HDAC1 Q13547 3/20 0.51
PLAU P00749 1/20 0.49
HDAC8 Q9BY41 2/20 0.47
HDAC2 Q92769 1/20 0.47
THRB P10828 1/20 0.45
CA2 P00918 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
WDR5 P61964 1/20 0.43
PRKCI P41743 1/20 0.43
PLK1 P53350 4/20 0.43
GAA P10253 2/20 0.43
SLC7A5 Q01650 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355600 0.85 HDAC6 (0.71) HDAC6HDAC1PLAUHDAC8HDAC2
SCHEMBL31213533 0.83 HDAC1 (0.53) HDAC6HDAC1CA2HTTWDR5
SCHEMBL5924147 0.83 HDAC1 (0.53) HDAC6HDAC1CA2HTTWDR5
SCHEMBL29582662 0.82 PLAU (0.53) HDAC6HDAC1PLAUHDAC8HDAC2
SCHEMBL940919 0.82 PLAU (0.53) HDAC6HDAC1PLAUHDAC8HDAC2
SCHEMBL30147734 0.82 CES2 (0.59) HDAC6HDAC1PLAUHDAC8HDAC2
SCHEMBL531941 0.82 CES2 (0.59) HDAC6HDAC1PLAUHDAC8HDAC2
SCHEMBL5596417 0.82 HDAC1 (0.49) HDAC6HDAC1HDAC8HDAC2HPGD
SCHEMBL21218842 0.81 HDAC1 (0.47) HDAC6HDAC1HTTWDR5
SCHEMBL603156 0.81 ALOX15 (0.53) HDAC6HDAC1THRBHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371987-B9 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-11-26 EP disclosed
EP-4371987-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-09-17 EP disclosed
US-12258346-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2025-03-25 US disclosed
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2024-08-29 US disclosed
CN-113227089-B Substituted 6-azabenzimidazole compounds as HPK1 inhibitors 吉利德科学公司 2024-07-05 CN disclosed
EP-4371987-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS Gilead Sciences, Inc. (US) 2024-05-22 EP disclosed
US-11897878-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2024-02-13 US disclosed
EP-3873903-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2024-01-24 EP disclosed
EP-3873903-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2024-01-24 EP disclosed
US-20220213091-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2022-07-07 US disclosed
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2021-04-22 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK HDAC6 1425/4885HDAC1 500/4885PLAU 3694/4885
US-12258346-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK HDAC6 1425/4885HDAC1 500/4885PLAU 3694/4885
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HDAC6 677/4885HDAC1 705/4885PLAU 3424/4885
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK HDAC6 1425/4885HDAC1 500/4885PLAU 3694/4885
US-20220213091-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK HDAC6 1425/4885HDAC1 500/4885PLAU 3694/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HDAC6 677/4885HDAC1 705/4885PLAU 3424/4885
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I HDAC6 287/4885HDAC1 265/4885PLAU 4717/4885
US-11897878-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK HDAC6 1425/4885HDAC1 500/4885PLAU 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.